Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!

References

• Al-Rasadi K, Al-Zakwani I, Al Mahmeedet W, et al. Therapeutic lipid target achievement among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf. Curr Med Res Opin 2014;30(12)2429-35
   Google Scholar
• Nair DR, Sharifi M, Al-Rasadi K. Familial hypercholesterolaemia. Curr Opin Cardiol 2014; 29:381-8
   PubMed Web of Science ®Google Scholar
• Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. Oman Med J 2014;29:85-91
   PubMedGoogle Scholar
• Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: a systematic review. PLoS One 2012;7:e40948
   PubMed Web of Science ®Google Scholar
• Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology 2011;62:381-9
   PubMed Web of Science ®Google Scholar
• Raal F, Schamroth C, Blom D, et al. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr 2011;22:234-40
   PubMed Web of Science ®Google Scholar
• Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012;19:781-94
   PubMed Web of Science ®Google Scholar
• Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445-54
   PubMed Web of Science ®Google Scholar
• van den Haak P, Heintjes E, Plat AW, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin 2010;26:271-8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Mikhailidis DP. Undertreatment of dyslipidaemia in Greece. Atherosclerosis 2004;173:353-61
   PubMedGoogle Scholar
• Diamantopoulos EJ, Athyros VG, Yfanti GK, et al.; OLYMPIC Study Group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology 2005;56:731-41
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Morant SV, Mozaffari E. Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. J Hum Hypertens 2007;21:925-33
   PubMed Web of Science ®Google Scholar
• Klingman D, Williams SA, Benner JS, et al. Gauging the treatment gap in dyslipidemia: findings from the 1999–2000 National Health and Nutrition Examination Survey. Am Heart J 2005;150:595-601
   PubMed Web of Science ®Google Scholar
• Kotseva K. EUROASPIRE IV – European Society of Cardiology Congress 2013, European Society of Cardiology Congress, 2013: A365. Available at: http://www.escardio.org/communities/EACPR/Documents/general-assembly-esc-congress-2012/4-EU-Forum-Kotseva.pdf. Last accessed 17 Sept 2014
   Google Scholar
• Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22
   PubMed Web of Science ®Google Scholar
• Hatzitolios AI, Athyros VG, Karagiannis A, et al.; IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 2009;134:322-9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. SAGE-METS collaborative group. Curr Med Res Opin 2009;25:971-80
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementation of guidelines for the management of arterial hypertension. The IMPULSION study. Open Cardiovasc Med J 2009;3:26-34
   PubMedGoogle Scholar
• Athyros VG, Hatzitolios AI, Karagiannis A, et al.; IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercholesterolemia. Curr Med Res Opin 2010;26:439-43
   PubMed Web of Science ®Google Scholar
• Doumas M, Tziomalos K, Athyros VG. Pay-for-performance versus a budget-restrictive system for the management of dyslipidemia. Should this approach also be applied in hypertension? Open Hypert J 2013;5:32-4
   Google Scholar
• Gitt AK, Juenger C, Smolka, et al. Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL goal achievement in statin-treated patients for secondary prevention: results of DYSIS. European Society of Cardiology 2013 Congress; September 2, 2013; Amsterdam, the Netherlands. Eur Heart J 2013;34(Abstract Suppl):3689
   Google Scholar
• Koenigsfeld CF, Horning KK, Logemann CD, Schmidt GA. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract 2012;25:89-95
   PubMedGoogle Scholar
• Mehta RH, Montoye CK, Gallogly M, et al.; GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA 2002;287:1269-76
   PubMed Web of Science ®Google Scholar
• Vasaiwala S, Nolan E, Ramanath VS, et al. A quality guarantee in acute coronary syndromes: the American College of Cardiology’s Guidelines Applied in Practice program taken real-time. Am Heart J 2007;153:16-21
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation 2010;121:586-613
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou Y, Gao X, et al. Ideal cardiovascular health metrics and the risks of ischemic and intracerebral hemorrhagic stroke. Stroke 2013;44:2451-6
   Google Scholar
• Bambs C, Kip KE, Dinga A, et al. Low prevalence of ‘ideal cardiovascular health’ in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study. Circulation 2011;123:850-7
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar